Mitsubishi Tanabe To Settle Japanese Hepatitis Suit
This article was originally published in PharmAsia News
Japan's Mitsubishi Tanabe Pharma and its subsidiary expect to reach another settlement in the long-running case of patients infected with hepatitis C by tainted drug products. One of the lawyers involved in suits against the company says they expect to settle as early as late August. Plaintiffs and their lawyers have been meeting with company representatives to resolve the suit. One of the lawyers said the Mitsubishi Tanabe board expects to deliberate a draft of an agreement similar to the one plaintiffs presented June 23 that requires an apology from executives of the parent plant and its Benesis subsidiary. Nihon Pharmaceutical also is named in the suit. (Click here for more
You may also be interested in...
The proposed rule from the US HHS that would require its agencies to review all regulations every 10 years could distract an incoming Biden administration from the COVID-19 pandemic and will “wreak havoc” on Medicare, a senior policy analyst for the Center on Budget and Policy Priorities says.
The pharmacy will be ready to begin COVID-19 vaccinations 48 hours after receiving the vaccine, Merlo said, outlining plans for a mass vaccination effort that will include online appointments.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.